A new way of treating cancer has shown “great promise” in its first clinical trial at the Royal Marsden Hospital in London.

Researchers gave olaparib, a drug being developed by AstraZeneca with the UK Institute for Cancer Research, to 60 patients with advanced breast, ovarian and prostate cancers. All had mutations in the BRCA1 and BRCA2 genes associated with inherited forms of these cancers.